tbuckley/cabot-search huggingface dataset:
An analysis of high ferritin levels before allogeneic hematopoietic cell transplantation (AlloHCT): A retrospective study to evaluate prognostic factors in patients (pts) undergoing AlloHCT for myelodysplasia.
Authors: S. Hashmi, E. S. Rich, S. Basu, J. J. Maciejewski, S. Nathan, P. Venugopal, S. A. Gregory, H. C. Fung, J. M. Shammo
Journal: Journal of Clinical Oncology (2011)

6562 Background: AlloHCT remains the only curative option for pts with myelodysplastic syndrome (MDS). We sought to identify, retrospectively, factors associated with better outcome after allografting. Methods: We conducted a comprehensive chart review of pts with MDS who underwent myeloablative AlloHCT from 1998 to 2010. Background, prognostic variables, and treatment regimens were analyzed to assess their impact on outcome. Results: 35 pts were transplanted between 1998 and 2010. Median age was 51 (range: 24-66); male to female ratio 1:1; related donor 46% (n=16); matched unrelated donor 54% (n=19). Cytogenetic risk group by IPSS: good, 40% (n=14), intermediate, 37% (n=13), poor, 23% (n=8). Graph type was peripheral blood in 80% (n=28) and bone marrow in 20% (n=7). Median overall survival was 316 days after transplant (range: 248-802). Survival was 77% at day (d) 100; 47% at 1 year (yr); 29% at 3 yr; 11 pts (31%) remain alive. The most common cause of death before d100 was infection and after d100 was GVHD. 8 pts (23%) had ferritin levels <1000 ng/ml before transplant, and in the remaining 27 pts (77%), ferritin levels were >1000 ng/ml. Median survival was five times greater in the group with ferritin levels <1000 ng/ml. At the time of transplantation, 46% (n=16) had progressed to AML; 54% (n=19) had MDS [RA n=5, RAEB-1 n=4, RAEB-2 n=3, RARS n=2, MDS/MPD n=3, CMML n=1, MDS unclassified n=1]. Median survival in MDS was 1157 days versus 109 days in AML (p=0.042). 9 pts (26%) received hypomethylators before transplant; none achieved complete remission (CR). 4 pts (11.4%) attained CR following induction chemotherapy. Although the “CR” group demonstrated a trend towards better survival, results were not statistically significant due to limited sample size. Conclusions: Our retrospective analysis identified several prognostic factors associated with improved survival following AlloHCT: MDS without evolution to AML, remission at d100, and ferritin level <1000 ng/ml. CR at the time of transplant may be associated with improved survival, but needs further confirmation.
Proline Starvation Induces Unresolved ER Stress and Hinders mTORC1-Dependent Tumorigenesis
Authors: Nisebita Sahu, Darlene Dela Cruz, Min Gao, Wendy Sandoval, Peter M. Haverty, Jinfeng Liu, Jean-Philippe Stephan, Benjamin Haley, Marie Classon, Georgia Hatzivassiliou, Jeff Settleman
Journal: Cell Metabolism (2016)
Commentary on Almassalha et al., “The Greater Genomic Landscape: The Heterogeneous Evolution of Cancer”
Authors: Henry T. Lynch, Marc Rendell, Trudy G. Shaw, Peter Silberstein, Binh T. Ngo
Journal: Cancer Research (2016)

In this issue of Cancer Research, Almassalha and colleagues have proposed a new concept of the development of malignancy, that of the greater genomic landscape. They propose a stressor-related exploration of intracellular genomic sites as a response mechanism. This process can express sites with beneficial or deleterious effects, among them those that promote cell proliferation. They point out that their conception is broader, although certainly inclusive, of the process of gene induction. The authors view the physical process of chromatin reorganization as central to the exploration of the genomic landscape. Accordingly, they advocate the development of agents to limit chromatin structural modification as a chemotherapeutic approach in cancer. We found their theory relevant to understand the phenotypic heterogeneity of malignancy, particularly in familial cancer syndromes. For example, the familial atypical multiple mole melanoma (FAMMM) syndrome, related to a gene mutation, is characterized by a diversity of melanocytic lesions, only some of which become malignant melanoma. This new conceptualization can do much to increase understanding of the diversity of malignancy in families with hereditary cancer. Cancer Res; 76(19); 5602-4. ©2016 AACR.
Abstract 12428: Efficacy of a Risk Reduction Program to Improve Cardiovascular Outcomes in Patients With Peripheral Arterial Disease: A Propensity Score-Matched Study
Authors: Mohamad A Hussain, Mohammed Al-Omran, Muhammad Mamdani, Xuesong Wang, Subodh Verma, Thomas Lindsay
Journal: Circulation (2015)

Introduction: Patients with peripheral arterial disease (PAD) are often undertreated for cardiovascular (CV) risk factors, and they are at high risk for CV events. Hypothesis: A program that focuses on guideline-based risk factor management reduces adverse CV and limb events in PAD patients. Methods: A propensity-score matched observational cohort study with up to 7 years of follow-up was conducted using administrative databases in Ontario, Canada. Symptomatic PAD patients that were enrolled in the Systematic Assessment of Vascular Risk (SAVR) program between July 2004 and April 2007 were matched with up to 2 (control) patients with PAD from other Ontario tertiary vascular centers not enrolled in the program. The primary outcome was a composite of death, stroke or myocardial infarction (MI). Secondary outcomes included lower limb amputation and revascularization procedures. Cox proportional hazards regression analysis was used to compare outcomes between the groups. Results: A total of 791 patients were studied. During follow-up, the SAVR group (n=290) experienced the primary outcome at a significantly lower rate than the control group (adjusted HR, 0.64 [95% CI, 0.52 to 0.78]; P&lt;0.001) (Figure). SAVR patients were also less likely to undergo major amputation (adjusted HR, 0.47 [95% CI, 0.29 to 0.77]; P=0.002), minor amputation (adjusted HR, 0.26 [95% CI, 0.13 to 0.54]; P&lt;0.001), arterial bypass surgery (adjusted HR, 0.47 [95% CI, 0.30 to 0.73]; P&lt;0.001), and less likely to have a hospitalization due to heart failure (adjusted HR, 0.73 [95% CI, 0.53 to 0.998]; P=0.048). The rate of peripheral angioplasty was higher among the SAVR group (adjusted HR, 3.0 [95% CI, 2.2 to 4.1]; P&lt;0.001). Conclusions: A multifactor risk reduction program targeted to patients with PAD is associated with fewer adverse CV and limb events over the long-term. Greater focus is needed on developing structured programs for risk factor control in these high-risk patients.
Concurrent chemoradiotherapy with cetuximab plus twice-weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal squamous cell carcinoma.
Authors: Chia-Chi J. Lin, Chih-Hung Hsu, Jason C. Cheng, Chueh-Chuan Yen, Her-Shyong Shiah, Ta-Chen Huang, Wei-Wu Chen, Hsiu-Po Wang, Kun-Huei Yeh, Jang-Ming Lee, Ann-Lii Cheng
Journal: Journal of Clinical Oncology (2013)

4099 Background: We investigated the efficacy and safety of adding cetuximab to twice-weekly paclitaxel/cisplatin-based concurrent chemoradiotherapy (CCRT), followed by surgery, for patients with locally advanced esophageal squamous cell carcinoma (ESCC). Methods: Patients with locally advanced ESCC (T3N0-1M0 or T1-3N1M0 or M1a by AJCC 2002) were treated with paclitaxel (35 mg/m 2 1 h D1, 4/wk), cisplatin (15 mg/m 2 1 h D2, 5/wk), cetuximab (400 mg/m 2 2 h D-5, then 250 mg/m 2 1 h D3/wk) and radiotherapy (2 Gy D1-5/wk). The feasibility of esophagectomy was evaluated for all patients at the accumulated radiation dose of 40 Gy. If esophagectomy was not feasible, CCRT was continued to a radiation dose of 60-66 Gy. Results: 66 patients were enrolled between Oct 2008 and Jun 2010, and 61 (94%) of them had T3N1M0 or M1a tumors by endoscopic ultrasonographic staging. All patients received CCRT to 40 Gy. Forty-three patients underwent surgery, and 17 patients continued definitive CCRT to 60-66 Gy. Of the scheduled doses of paclitaxel, cisplatin, and cetuximab, 80%, 79%, and 99% were given, respectively. The most common grade 3/4 toxic effects were leukopenia (51%), neutropenia (15%), esophagitis (19%), and infection (12%). The pathological complete response rate was 24% (intent-to-treat, 16/66) (95% confidence interval: 13-35%) and 37% (who underwent resection, 16/43). At the median follow-up of 34.6 months, the median progression-free (PFS) and overall survivals were 21.6 and 33.9 months, respectively. No KRAS codon 12/13 mutations were identified in 47 tumor samples. The median PFS for patients with two, one, and no adverse tumor biomarkers (Tau+, ERCC1+, pEGFR-) (n = 40) was 12.3 months, 27.6 months, and greater than 33.6 months, respectively (p = .087). Conclusions: Adding cetuximab to twice-weekly paclitaxel/cisplatin-based CCRT prior to esophagectomy is an active and tolerable treatment for locally advanced ESCC. Clinical trial information: NCT01034189. [Table: see text]
P1-102: Correlation of [18F]FDG PET/CT imaging with Glut-1 and Glut-3 expression in non-small cell lung cancer
Authors: Ie Ryung Yoo, W.H. Choi, T.J. Kim, K.Y. Lee, Y.P. Wang, H.J. Park, S.J. Kim, Y.S. Kim, J.H. Kang, Y.K. Kim
Journal: Journal of Thoracic Oncology (2007)
Dermatology and Possession
Authors: Chu Hsiao, Eric Laurent Maranda, William A. Estes, Gabriela M. Soza, Keyvan Nouri
Journal: JAMA Dermatology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Recipient-Type Leucocyte Infusion After Allohsct in Mice Slows Local Growth of Neuroblastoma and Elicits Activation of Intratumoral Cytotoxic NK Cells
Authors: Leen Willems, Omer Rutgeerts, Caroline Lenaerts, Stefaan Van Gool, Mark Waer, An Billiau
Journal: Blood (2012)
Panitumumab (pmab) plus AMG 102 in patients (pts) with wild-type <i>KRAS</i> metastatic colorectal cancer (mCRC): Updated safety results.
Authors: C. Eng, J. Tabernero, E. Nowara, A. Swieboda-Sadlej, N. C. Tebbutt, E. P. Mitchell, I. Davidenko, L. Chen, D. Smethurst, E. Van Cutsem
Journal: Journal of Clinical Oncology (2010)

e14083 Background: AMG 102 is an investigational, fully human monoclonal antibody (mAb) against human hepatocyte growth factor. This study is evaluating safety and tolerability of AMG 102 combined with pmab, a fully human mAb against the epidermal growth factor receptor, for treatment of mCRC. Methods: This was the phase Ib, open-label, dose-finding portion of a three-part trial. Part 1 was to determine the MTD of AMG 102 + pmab; parts 2 and 3 comprise the phase II 3-arm (pmab vs. pmab + AMG 102 vs. pmab + AMG 479 [a fully human mAb against insulin-like growth factor receptor type 1]) randomized trial and extension study, respectively. Eligible pts were ≥ 18 years of age, had wild-type KRAS mCRC, and ECOG PS 0/1. All pts received pmab 6 mg/kg IV plus AMG 102 at 10 mg/kg IV Q2W until disease progression (PD) or intolerability. An additional cohort (5 mg/kg) was planned if the 10 mg/kg dose was intolerable based on the incidence of dose-limiting toxicities (DLTs; grade 3/4 AMG 102-related or combination therapy [AMG 102 + pmab]-related adverse event [AE] deemed clinically significant by the investigator). The primary endpoint was incidence of DLTs. Data from the first 6 DLT-evaluable pts were used to determine the dose for part 2. Results: No DLT has been reported for the first 6 DLT-evaluable subjects. The 10 mg/kg Q2W dose has been selected as the phase II dose. Accrual to part 1 was not halted until the dose escalation decision was made. 11 pts have enrolled in part 1; 5 pts were men; mean age was 56 years (range 37–75); ECOG 0/1 = 64%/36%. No grade 4 or 5 treatment (pmab or AMG 102)-related AEs have been reported (table). Serious AEs (related and unrelated) included acneiform dermatitis (n = 1), intestinal obstruction (n = 1), cerebrovascular accident (n = 1), capillary leak (n = 1), anemia and general health deterioration (n = 1). 1 pt died on study from PD. Conclusions: To date, AMG 102 combined with pmab for the treatment of mCRC is well tolerated. The combination therapy in part 2 is currently being evaluated. Treatment-related AEs*—n (%) Pmab + AMG 102 (N = 11) Acneiform dermatitis or rash 6 (55) Infection 2 (18) Paronychia 2 (18) Capillary leak syndrome 1 (9) Erythema 1 (9) Nail disorder 1 (9) Pruritus 1 (9) * All events were grade 3. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Amgen Amgen Amgen Amgen Amgen Amgen
Self-expandable metal stents as definitive treatment for esophageal variceal bleeding
Authors: I. Holster, E. Kuipers, H. van Buuren, M. Spaander, E. Tjwa
Journal: Endoscopy (2013)

The use of self-expandable metal stents (SEMS) has occasionally been described for the treatment of uncontrollable esophageal variceal bleeding (EVB) as a bridge to an alternative treatment option (i. e. transjugular intrahepatic portosystemic shunt [TIPS]). It is currently not known whether SEMS placement is appropriate for more than temporary hemostasis. This case series report describes five patients in whom EVB could not be controlled with variceal band ligation and who were not suitable to undergo a TIPS procedure at the time of bleeding. SEMS were placed in these patients with the intent of definitive treatment. Successful initial hemostasis was achieved in all five patients, and sustained hemostasis occurred in four. Stents were removed from two patients after > 14 days and remained in situ until death in three other patients (range 6 – 214 days). No complications related to this longer duration were observed. In one case, TIPS could be performed at a later stage. SEMS could be a definitive treatment for uncontrollable esophageal bleeding in patients with a limited life expectancy or those unsuitable for TIPS at the time of bleeding.
Combination therapy with paclitaxel, carboplatin, and megesterol acetate for advanced-stage and recurrent endometrial carcinoma: A phase II study.
Authors: K. S. Bevis, L. C. Kilgore, R. D. Alvarez, J. M. Straughn, C. A. Leath
Journal: Journal of Clinical Oncology (2010)

5093 Background: Data is limited regarding combination chemotherapy and hormonal therapy in patients with recurrent or advanced endometrial cancer (EMCA). The purpose of the current study is to determine overall survival, progression-free interval, and toxicity in patients with advanced or recurrent EMCA treated with combination paclitaxel, carboplatin, and megesterol acetate (Megace). Methods: Patients with FIGO Stage III-IV or recurrent EMCA were enrolled between 10/2004 and 4/2008. Patients received paclitaxel (175 mg/m2) and carboplatin (AUC 6) every 21 days for 6 cycles and Megace 40 mg orally four times daily for up to 5 years in the absence of progression. Following completion of paclitaxel and carboplatin, patients were followed every 4 to 6 months for 5 years. Disease status was assessed via serial CT studies and physical exams. Prescribed dose reductions were based on grade 3/4 thrombocytopenia or neutropenia. Colony-stimulating factors were administered for persistent grade 3/4 neutropenia. Survival data was calculated from time of study enrollment. Results: Twenty-eight patients were evaluable. Twenty (71%) patients had stage III-IV primary disease and 8 (29%) patients had recurrent disease. Median overall survival was 36.3 months (4.7-49.5). Median progression-free interval was 31.9 months (2.3-49.5). After a median 28.2 months of follow-up, 14 patients (50%) were NED, 4 were AWD, and 9 were DOD. One patient died without evidence of disease. Twenty-three patients completed 6 cycles of chemotherapy. Ten patients experienced a dose reduction. Myelosuppression was the most common toxicity with 13 patients (48%) experiencing grade 3/4 neutropenia, and 9 patients (33%) experiencing grade 3/4 anemia. There were no episodes of febrile neutropenia. Three patients had a deep vein thrombosis. One patient experienced a pulmonary thromboembolus. Conclusions: Combination therapy with paclitaxel, carboplatin, and Megace has excellent activity in patients with advanced and recurrent EMCA. The addition of hormonal therapy to chemotherapy is safe and may improve survival. Myelosuppression is common, but can be managed with colony-stimulating factors. No significant financial relationships to disclose.
Pneumonitis in non-small cell lung cancer (NSCLC) patients treated with programmed death 1 (PD1) axis inhibitors.
Authors: Scott N. Gettinger, Xuchen Zhang, Robert Homer, Jennifer Possick, Anna Wurtz, Sarah B. Goldberg, Anne C. Chiang, Roy S. Herbst, Ami Rubinowitz
Journal: Journal of Clinical Oncology (2016)

9030 Background: Pneumonitis (P) has been reported in up to 6% of patients (pts) with advanced NSCLC receiving anti- PD1 or PD ligand 1 (PDL1) antibodies (Ab), with potential for fatality if not recognized and treated expeditiously. Methods: Pts with advanced NSCLC who developed P while receiving an anti- PD1 or PDL1 Ab on clinical trial were identified. Serial imaging studies/ pathology were reviewed with a thoracic radiologist/ pathologist. Results: 24 pts were identified with P, 21 with bronchoscopic sampling. 16 pts received anti-PD1, 2 anti-PDL1, 1 anti-PDL1 + chemotherapy, and 5 anti-PD1 or anti-PDL1 + anti-CTLA4 Ab; objective response rate (RECIST) was 50%. Median age, 75 years (range, 47-89); female/ male, 9/ 15; squamous/ non-squamous histology, 6/ 18; never smoker/ smoker, 3/ 21. All pts were Caucasian. Median onset of P was 75 days (range, 8-549). 19 pts were treated with steroids; P resolved to grade 1 or 0 in all cases. 6 pts were re-challenged with anti- PD1/ PDL1 after steroid taper, 4 developed recurrent P. Three distinct radiographic patterns of P were appreciated: Type 1, organizing pneumonia (consolidation +/- ground glass opacity with a peripheral/ peribronchovascular distribution); Type 2, ground glass opacity (diffuse or focal ground glass opacities); Type 3, nodular (perilymphatic or centrilobular nodules). 52/ 28/ 8% of pts had pure Type 1/ 2/ 3 (1 pt had different pattern with recurrent P). 12% had mixed patterns (2 with Type 1 + 2; 1 with Type 1 + 3). 22 cases involved more than 1 lobe of the lung. 3 pts had primarily peri-tumoral opacities. Transbronchial biopsies were available on 20 pts: all had varying degrees of lymphocytic infiltrate (mainly T cells), 7 had granulomas, 8 had eosinophils (including 2 with granuloma). CD4/ CD8 staining was available in 19 cases, with predominance of CD8+ cells; mean CD4/CD8 ratio, 0.46. Conclusions: P is a rare but treatable complication of PD1 axis inhibitor therapy, with distinct radiographic patterns (organizing pneumonia, ground glass opacity and nodular) and pathological features (granulomatous vs non-granulomatous inflammation). Additional ongoing characterization of immune infiltrate may help to elucidate mechanisms of P with PD1 axis inhibitors.
P2-283: Dose individualization of Carboplatin in elderly patients with advanced non small cell lung cancer (ANSCLC): an exploratory analysis
Authors: Matilde Merino, Inmaculada Maestu, Daniel Almenar, N víctor Jiménez, Mónica Tallón, José Muñoz, Vicente G. Casabó
Journal: Journal of Thoracic Oncology (2007)
Randomized, multicenter, phase III trial to compare S-1 plus docetaxel (DS) with S-1 plus cisplatin (SP) in gastric cancer patients with stage III (POST trial).
Authors: Choong-kun Lee, Minkyu Jung, Seok Yun Kang, Bong-Seog Kim, Ki Hyang Kim, Kyung Hee Lee, Moon Hee Lee, Dong Bok Shin, Dae Young Zang, Ji Yeong Ahn, Hyoung-Il Kim, Woo Jin Hyung, Sung Hoon Noh, Hyo Song Kim, Hyun Cheol Chung, Sun Young Rha
Journal: Journal of Clinical Oncology (2014)

4069 Background: Even among completely resected gastric cancer patients treated with adjuvant chemotherapy, stage III patients show bad prognosis and somewhat better treatment option is needed. Docetaxel or cisplatin each added to S1 monotherapy showed survival benefits in advanced gastric cancer. Methods: We conducted randomized, multicenter, phase III trial to compare S-1 plus docetaxel (DS) with S1 plus cisplatin (SP) in stage III gastric cancer patients. Gastric cancer patients (AJCC 7th stage III) who had had curative D2 gastrectomy were randomized 1:1 to receive adjuvant chemotherapy of eight 3 week cycles of DS (S-1 70mg/m2/day on day 1-14 plus docetaxel 35mg/m2 on day 1, and day 8) or SP (S-1 70mg/m2/day on day 1-14 plus cisplatin 60mg/m2on day 1). The primary endpoint was 3-year disease-free survival (3Y-DFS). Secondary endpoints include overall survival (OS) and safety. (NCT01283217) Results: As a result of early closure due to slow accrual, 153 patients of planned 290 patients were randomly assigned (75 patients to DS and 78 patients to SP) from 8 institutions for 31 months. The median follow up duration was 15.8 months (range, 0.8 to 36.2 months). There was no difference in DFS (HR, 1.088; 95% CI, 0.589 to 2.01; p=0.787) or OS (HR, 1.621; 95% CI, 0.707 to 3.720; p=0.254) between DS and SP. Most common grade 3 or 4 adverse event was neutropenia (42.7% among DS group and 38.5% among SP group, p=0.351). SP group suffered more grade 3 or 4 anemia (1.3% vs. 11.5%, p=0.037), where grade 3 or 4 hand-foot syndrome (4.1% vs. 0%, p=0.025) and mucositis (10.7% vs. 2.6%, p=0.001) were more common among DS group. Conclusions: Although the trial closed prematurely and had short follow up duration, S-1 plus cisplatin or docetaxel is an effective and tolerable option for patients with stage III advanced gastric cancer patients. Clinical trial information: NCT01283217.
Altered Hematopoietic Cell Gene Expression Identifies Patients at Risk for Development of Therapy-Related Leukemia (t-MDS/AML)
Authors: Liang Li, Min Li, Can-Lan Sun, Liton Francisco, Melanie Sabado, Tinisha McDonald, Janelle Gyorffy, Karen Chang, Shirong Wang, Wenhong Fan, Jiangning Li, Lue Ping Zhao, Jerald Radich, Stephen J. Forman, Smita Bhatia, Ravi Bhatia
Journal: Blood (2010)
Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B Study (CALGB 10503)
Authors: W Blum, B L Sanford, R Klisovic, D J DeAngelo, G Uy, B L Powell, W Stock, M R Baer, J E Kolitz, E S Wang, E Hoke, K Mrózek, J Kohlschmidt, C D Bloomfield, S Geyer, G Marcucci, R M Stone, R A Larson
Journal: Leukemia (2016)